These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30320573)

  • 21. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.
    Morris JC
    Arch Neurol; 2012 Jun; 69(6):700-8. PubMed ID: 22312163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.
    Besser LM; Litvan I; Monsell SE; Mock C; Weintraub S; Zhou XH; Kukull W
    Parkinsonism Relat Disord; 2016 Jun; 27():54-60. PubMed ID: 27089852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal.
    Roberts RO; Knopman DS; Mielke MM; Cha RH; Pankratz VS; Christianson TJ; Geda YE; Boeve BF; Ivnik RJ; Tangalos EG; Rocca WA; Petersen RC
    Neurology; 2014 Jan; 82(4):317-25. PubMed ID: 24353333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
    Scarabino D; Broggio E; Gambina G; Maida C; Gaudio MR; Corbo RM
    Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1131-1138. PubMed ID: 27604972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults.
    Trzepacz PT; Hochstetler H; Wang S; Walker B; Saykin AJ;
    BMC Geriatr; 2015 Sep; 15():107. PubMed ID: 26346644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.
    Hall A; Muñoz-Ruiz M; Mattila J; Koikkalainen J; Tsolaki M; Mecocci P; Kloszewska I; Vellas B; Lovestone S; Visser PJ; Lötjonen J; Soininen H; ; ;
    J Alzheimers Dis; 2015; 44(1):79-92. PubMed ID: 25201784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
    Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
    Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway.
    Strand BH; Knapskog AB; Persson K; Edwin TH; Amland R; Mjørud M; Bjertness E; Engedal K; Selbæk G
    PLoS One; 2018; 13(9):e0204436. PubMed ID: 30240425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years.
    Albert M; Zhu Y; Moghekar A; Mori S; Miller MI; Soldan A; Pettigrew C; Selnes O; Li S; Wang MC
    Brain; 2018 Mar; 141(3):877-887. PubMed ID: 29365053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population.
    Prins ND; van der Flier WM; Brashear HR; Knol DL; van de Pol LA; Barkhof F; Scheltens P
    J Alzheimers Dis; 2013; 36(1):79-85. PubMed ID: 23563246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study.
    Di Carlo A; Baldereschi M; Lamassa M; Bovis F; Inzitari M; Solfrizzi V; Panza F; Galluzzo L; Scafato E; Inzitari D;
    J Alzheimers Dis; 2016 May; 53(2):505-15. PubMed ID: 27163817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Normative Adjustments to the Montreal Cognitive Assessment.
    Pugh EA; Kemp EC; van Dyck CH; Mecca AP; Sharp ES;
    Am J Geriatr Psychiatry; 2018 Dec; 26(12):1258-1267. PubMed ID: 30314940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama.
    Villarreal AE; Grajales S; O'Bryant SE; Edwards M; López L; Montalván A; Britton GB;
    J Alzheimers Dis; 2016 Oct; 54(3):897-901. PubMed ID: 27567849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved.
    Espinosa A; Alegret M; Valero S; Vinyes-Junqué G; Hernández I; Mauleón A; Rosende-Roca M; Ruiz A; López O; Tárraga L; Boada M
    J Alzheimers Dis; 2013; 34(3):769-80. PubMed ID: 23271318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comorbid Mild Cognitive Impairment and Depressive Symptoms Predict Future Dementia in Community Older Adults: A 24-Month Follow-Up Longitudinal Study.
    Makizako H; Shimada H; Doi T; Tsutsumimoto K; Hotta R; Nakakubo S; Makino K; Suzuki T
    J Alzheimers Dis; 2016 Oct; 54(4):1473-1482. PubMed ID: 27589518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical index to predict progression from mild cognitive impairment to dementia due to Alzheimer's disease.
    Lee SJ; Ritchie CS; Yaffe K; Stijacic Cenzer I; Barnes DE
    PLoS One; 2014; 9(12):e113535. PubMed ID: 25486250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative.
    Thomas KR; Eppig JS; Weigand AJ; Edmonds EC; Wong CG; Jak AJ; Delano-Wood L; Galasko DR; Salmon DP; Edland SD; Bondi MW;
    Alzheimers Dement; 2019 Apr; 15(4):561-569. PubMed ID: 30610833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.